

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

NCI-ADR-RES

RRID:CVCL_1452

Type: Cell Line

Proper Citation

RRID:CVCL_1452

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1452

Proper Citation: RRID:CVCL_1452

Description: Cell line NCI-ADR-RES is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:9331090](#), [PMID:9625176](#), [PMID:10700174](#), [PMID:11416159](#), [PMID:15748285](#), [PMID:16504380](#), [PMID:17088437](#), [PMID:18304946](#), [PMID:19372543](#), [PMID:20143388](#), [PMID:21116879](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22628656](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:27377824](#), [PMID:27807467](#), [PMID:31733513](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Problematic cell line: Contaminated. Shown to be a OVCAR-8 derivative (PubMed=16504380; PubMed=18304946; PubMed=20143388). Originally thought to be a derivative of MCF-7..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-ADR-RES

Synonyms: NCI/ADR-RES, NCI.ADR.RES, NCIADR.RES, NCI/ADRRES, NCIADRRES, ADR-RES, MCF-7/ADR, MCF-7/ADR-RES, MCF-7/AdrR, MCF-7/Adr, MCF-7/adr, MCF-7ADR, MCF7-ADR, MCF7ADR, OVCAR-8/ADR, OVCAR8/ADR

Cross References: BTO:BTO_0004181, MCCL:MCC:0000310, ArrayExpress:E-MTAB-783, BioGRID_ORCS_Cell_line:390, BioSample:SAMN03151880, BioSample:SAMN03151881, cancercellines:CVCL_1452, CancerTools:161022,

Cell_Model_Passport:SIDM00089, ChEMBL-Cells:CHEMBL3308057, ChEMBL-Targets:CHEMBL613829, Cosmic:687498, Cosmic:897420, Cosmic:905987, Cosmic:974233, Cosmic:1044218, Cosmic:1092617, Cosmic:1312358, Cosmic:1998459, GEO:GSM2099, GEO:GSM50197, GEO:GSM50260, GEO:GSM743473, GEO:GSM750832, GEO:GSM799367, GEO:GSM799430, GEO:GSM839041, GEO:GSM844614, GEO:GSM844615, GEO:GSM847073, GEO:GSM1153433, GEO:GSM1181271, GEO:GSM1181300, GEO:GSM2124672, IARC_TP53:21533, NCI-DTP:NCI/ADRRES, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, Progenetix:CVCL_1452, PubChem_Cell_line:CVCL_1452, SKY/M-FISH/CGH:2897, Wikidata:Q54907717

ID: CVCL_1452

Hierarchy: cvcl_1629

Record Creation Time: 20220427T220836+0000

Record Last Update: 20260905T181239+0000

Ratings and Alerts

No rating or validation information has been found for NCI-ADR-RES.

Warning: Problematic cell line: Contaminated. Shown to be a OVCAR-8 derivative (PubMed=16504380; PubMed=18304946; PubMed=20143388). Originally thought to be a derivative of MCF-7.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00234.

Population: Caucasian., Part of: NCI-60 cancer cell line panel., Problematic cell line: Contaminated. Shown to be a OVCAR-8 derivative (PubMed=16504380; PubMed=18304946; PubMed=20143388). Originally thought to be a derivative of MCF-7..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 363 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhu H, et al. (2026) Rhamnetin Identified as a Potent Multidrug Resistance Reversal Agent From Xinjiang Euphorbia: Integrated Network Pharmacology, Molecular Simulation, and In Vitro Validation. Chemistry & biodiversity, 23(4), e01952.

Rahman I, et al. (2026) Self-assembled verteporfin nanoparticles decrease drug efflux by P-glycoprotein without light activation in drug-resistant cancer cells. Bioengineering & translational medicine, 11(4), e70136.

- Bischof K, et al. (2024) Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways. *Molecular oncology*.
- Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.
- Kim CH, et al. (2023) Functionalized Lipid Nanocarriers for Simultaneous Delivery of Docetaxel and Tariquidar to Chemoresistant Cancer Cells. *Pharmaceuticals (Basel, Switzerland)*, 16(3).
- Peng H, et al. (2023) Defect self-assembly of metal-organic framework triggers ferroptosis to overcome resistance. *Bioactive materials*, 19, 1.
- Zhang T, et al. (2023) Enhanced therapeutic efficacy of doxorubicin against multidrug-resistant breast cancer with reduced cardiotoxicity. *Drug delivery*, 30(1), 2189118.
- Wang C, et al. (2023) Design, Synthesis, and Biological Evaluation of Marine Lissodendrins B Analogues as Modulators of ABCB1-Mediated Multidrug Resistance. *Marine drugs*, 21(5).
- Han E, et al. (2023) Development of Polymersomes Co-Delivering Doxorubicin and Melittin to Overcome Multidrug Resistance. *Molecules (Basel, Switzerland)*, 28(3).
- Pan M, et al. (2023) Poly(L-Ornithine)-Based Polymeric Micelles as pH-Responsive Macromolecular Anticancer Agents. *Pharmaceutics*, 15(4).
- Mukhtar MH, et al. (2023) Cymbopogon citratus and Citral Overcome Doxorubicin Resistance in Cancer Cells via Modulating the Drug's Metabolism, Toxicity, and Multidrug Transporters. *Molecules (Basel, Switzerland)*, 28(8).
- Shao W, et al. (2023) Cyperotundone combined with adriamycin induces apoptosis in MCF-7 and MCF-7/ADR cancer cells by ROS generation and NRF2/ARE signaling pathway. *Scientific reports*, 13(1), 1384.
- Wang R, et al. (2023) Tumor microenvironment-responsive micelles assembled from a prodrug of mitoxantrone and 1-methyl tryptophan for enhanced chemo-immunotherapy. *Drug delivery*, 30(1), 2182254.
- Jian FX, et al. (2023) Negative regulation of CD44st by miR-138-5p affects the invasive ability of breast cancer cells and patient prognosis after breast cancer surgery. *BMC cancer*, 23(1), 269.
- Zhao S, et al. (2023) Design, synthesis and anti-breast cancer properties of butyric ester tethered dihydroartemisinin-isatin hybrids. *Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents*, 32(4), 705.
- Chen Z, et al. (2023) Hypoxia-ameliorated photothermal manganese dioxide nanoplatfrom for reversing doxorubicin resistance. *Frontiers in pharmacology*, 14, 1133011.

Li Y, et al. (2023) Ethane groups modified DNA nanopores to prolong the dwell time on live cell membranes for transmembrane transport. *Frontiers in chemistry*, 11, 1148699.

Miri A, et al. (2023) Identification of co-regulated genes associated with doxorubicin resistance in the MCF-7/ADR cancer cell line. *Frontiers in oncology*, 13, 1135836.

Abdelaziz MH, et al. (2023) A Novel Electrochemical Differentiation between Exosomal-RNA of Breast Cancer MCF7 and MCF7/ADR-Resistant Cells. *Pharmaceuticals (Basel, Switzerland)*, 16(4).

Ju R, et al. (2023) Dual Sensitization Anti-Resistant Nanoparticles for Treating Refractory Breast Cancers via Apoptosis-Inducing. *Drug design, development and therapy*, 17, 403.